Adjusted clinical and utilisation outcomes over 12-month follow-up
| Adjusted OR* (95% CI) | |
| Adjusted clinical outcomes over 12 months of follow-up | |
| Implantable loop recorder | |
| New atrial fibrillation diagnosis | 1.89 (1.76 to 2.02) |
| New atrial fibrillation diagnosis and anticoagulant initiation | 2.27 (2.09 to 2.48) |
| Haemorrhagic stroke | 1.60 (1.34 to 1.93) |
| Major gastrointestinal bleeding | 1.02 (0.91 to 1.14) |
| Other major bleeding | 1.11 (0.84 to 1.46) |
| Other minor bleeding | 1.06 (0.97 to 1.16) |
| Holter monitor | |
| New atrial fibrillation diagnosis | 0.57 (0.52 to 0.62) |
| New atrial fibrillation diagnosis and anticoagulant initiation | 0.54 (0.48 to 0.62) |
| Haemorrhagic stroke | 0.87 (0.70 to 1.08) |
| Major gastrointestinal bleeding | 1.04 (0.94 to 1.16) |
| Other major bleeding | 0.71 (0.51 to 0.97) |
| Other minor bleeding | 1.10 (1.01 to 1.19) |
| Adjusted utilisation outcomes over 12 months of follow-up | |
| Implantable loop recorder | |
| All-cause acute inpatient | 1.13 (1.06 to 1.21) |
| All-cause emergency department | 1.04 (0.99 to 1.10) |
| Holter monitor | |
| All-cause acute inpatient | 0.99 (0.93 to 1.05) |
| All-cause emergency department | 0.93 (0.88 to 0.98) |
The reference group for all models is the long-term external continuous cardiac monitor (>48 hours to 30 days) group.
*All models adjusted for CHA2DS2-VASc score.